Inozyme Pharma (INZY) Competitors $2.99 +0.18 (+6.41%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INZY vs. AVXL, IMNM, KURA, KROS, TYRA, CRON, ERAS, EOLS, RAPP, and DNTHShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Cronos Group (CRON), Erasca (ERAS), Evolus (EOLS), Rapport Therapeutics (RAPP), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Cronos Group Erasca Evolus Rapport Therapeutics Dianthus Therapeutics Inozyme Pharma (NASDAQ:INZY) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Does the MarketBeat Community prefer INZY or AVXL? Anavex Life Sciences received 380 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 86.44% of users gave Inozyme Pharma an outperform vote while only 74.44% of users gave Anavex Life Sciences an outperform vote. CompanyUnderperformOutperformInozyme PharmaOutperform Votes5186.44% Underperform Votes813.56%Anavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% Which has more risk & volatility, INZY or AVXL? Inozyme Pharma has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Does the media favor INZY or AVXL? In the previous week, Inozyme Pharma and Inozyme Pharma both had 3 articles in the media. Anavex Life Sciences' average media sentiment score of 0.66 beat Inozyme Pharma's score of 0.34 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inozyme Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend INZY or AVXL? Inozyme Pharma presently has a consensus price target of $17.00, suggesting a potential upside of 468.56%. Anavex Life Sciences has a consensus price target of $43.00, suggesting a potential upside of 398.26%. Given Inozyme Pharma's higher possible upside, equities analysts plainly believe Inozyme Pharma is more favorable than Anavex Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has better valuation and earnings, INZY or AVXL? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInozyme PharmaN/AN/A-$71.17M-$1.56-1.92Anavex Life SciencesN/AN/A-$47.51M-$0.50-17.26 Do institutionals & insiders have more ownership in INZY or AVXL? 88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is INZY or AVXL more profitable? Anavex Life Sciences' return on equity of -30.64% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Inozyme PharmaN/A -88.42% -57.02% Anavex Life Sciences N/A -30.64%-28.23% SummaryAnavex Life Sciences beats Inozyme Pharma on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.08M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.9210.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.325.104.794.78Net Income-$71.17M$151.51M$120.07M$225.60M7 Day Performance-1.32%-2.14%-1.90%-1.24%1 Month Performance11.15%-3.13%11.43%3.06%1 Year Performance-26.54%11.51%30.59%16.50% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma1.8652 of 5 stars$2.99+6.4%$17.00+468.6%-23.7%$192.08MN/A-1.9250High Trading VolumeAVXLAnavex Life Sciences3.3412 of 5 stars$9.33+10.3%$43.00+360.9%-2.5%$791.18MN/A-18.3640IMNMImmunome2.561 of 5 stars$12.44-1.1%$28.83+131.8%+33.0%$776.47M$10.13M-1.5540Positive NewsKURAKura Oncology4.4841 of 5 stars$9.89+2.7%$29.38+197.0%-27.0%$769.05MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.92+0.5%$81.33+329.9%-49.6%$766.39M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0686 of 5 stars$14.99+0.3%$31.00+106.8%+2.0%$758.49MN/A-9.2820CRONCronos Group1.8534 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageERASErasca2.0792 of 5 stars$2.60+1.6%$5.90+126.9%+35.8%$735.09MN/A-3.08126News CoveragePositive NewsEOLSEvolus3.8237 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170RAPPRapport Therapeutics1.5264 of 5 stars$19.70+5.0%$35.00+77.7%N/A$720.63MN/A0.00N/ADNTHDianthus Therapeutics1.3337 of 5 stars$24.21+1.7%$46.43+91.8%+213.2%$716.62M$2.83M-9.5280Analyst ForecastNews Coverage Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Immunome Alternatives Kura Oncology Alternatives Keros Therapeutics Alternatives Tyra Biosciences Alternatives Cronos Group Alternatives Erasca Alternatives Evolus Alternatives Rapport Therapeutics Alternatives Dianthus Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INZY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
